



Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from <https://aidsinfo.nih.gov/guidelines> on 7/11/2017

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <https://aidsinfo.nih.gov/e-news>.

Management of Children Receiving Antiretroviral Therapy (Last updated April 27, 2017; last reviewed April 27, 2017)

In the United States, the majority of children living with HIV are receiving antiretroviral therapy (ART), making treatment-experienced children the norm. Changes in the antiretroviral (ARV) regimen and other aspects of the management of treatment-experienced children can be organized into the following categories:

1. Modifying ARV regimens in children on effective ART for simplification or improved adverse event (AE) profile;
2. Recognizing and managing ARV drug toxicity or intolerance (see [Management of Medication Toxicity or Intolerance](#));
3. Recognizing and managing treatment failure; and
4. Considerations about interruptions in therapy.

Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy

Panel's Recommendations
<ul style="list-style-type: none">• Children who have sustained virologic suppression on their current regimen should be regularly evaluated for opportunities to change to a new regimen that facilitates adherence, simplifies antiretroviral (ARV) administration, increases ARV potency, and decreases the risk of drug-associated toxicity (All).• Past episodes of antiretroviral therapy failure, tolerability, and all prior drug resistance testing results should be considered in order to avoid choosing new ARV drugs for which archived drug resistance would limit activity (All).
<p>Rating of Recommendations: A = Strong; B = Moderate; C = Optional</p> <p>Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion</p> <p>[†] Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents</p>

Initial ARV regimens are chosen based on safety, pharmacokinetic and efficacy data for drugs available in formulations suitable for the age of the child at initiation of ART. New ARV options may become available as children grow and learn to swallow pills and as new drugs, drug formulations, and data become available. Even in the setting of sustained virologic suppression (e.g., 6–12 months) on their current regimen, changing to a new ARV regimen may be considered in order to permit use of pills instead of liquids, reduce pill burden, allow use of once-daily medications, reduce risk of AEs, and align their regimens with widely used, efficacious adult regimens.¹ **Often the changes enhance adherence and improve quality of life.²**

Several studies have addressed switching ARV regimen components in children with sustained virologic suppression. Based on the NEVEREST 2 study, young children (i.e., aged <2 years) with virologic suppression who switch from lopinavir/ritonavir (LPV/r) to nevirapine can maintain virologic suppression as well as those who continue LPV/r, provided there is good adherence and no baseline resistance to nevirapine.^{3,4} In the NEVEREST 3 study, children ≥3 years of age with a history of exposure to nevirapine and with virologic suppression on LPV/r maintained virologic suppression when switched from LPV/r to efavirenz.^{5,6} **Similarly, in the NEVEREST 2 study, children switched to a nevirapine regimen showed better immune and growth responses than those continuing a LPV/r regimen.³** By extrapolation, replacement of LPV/r with an equally potent protease inhibitor (PI) (e.g., darunavir, atazanavir), **or an integrase inhibitor (INSTI) (e.g., elvitegravir, raltegravir, dolutegravir)** would likely be effective, but that has not been directly

studied. Several small studies have demonstrated sustained virologic suppression and reassuring safety outcomes when drugs that have greater long-term toxicity risk are replaced with drugs that are thought to have less toxicity risk (e.g., replacing stavudine with tenofovir disoproxil fumarate, **tenofovir alafenamide**, zidovudine, or abacavir; replacing PIs with non-nucleoside reverse transcriptase inhibitors), including improved lipid profiles, in small cohorts of children.⁷⁻¹¹ Small studies have shown that children with virologic suppression on certain twice-daily regimens (i.e., abacavir, nevirapine) maintain virologic suppression if changed from twice daily to once daily (see [Abacavir](#) and [Nevirapine](#) drug sections) but show mixed results when switching LPV/r dosing from twice daily to once daily; therefore, once-daily LPV/r is not recommended **in children aged <12 years or <30kg**.¹²⁻¹⁵

Dual and monotherapy protease inhibitor (darunavir/ritonavir, LPV/r, atazanavir/ritonavir) and INSTI (dolutegravir) strategies in adult patients with sustained virologic suppression for the purposes of simplification or reduced toxicity have been attempted with varying success. They are being further explored, but are not currently recommended as a management strategy. Limited studies have been done in children and these strategies cannot be endorsed at this time.¹⁶⁻²⁰

Table 14 displays examples of changes in ARV regimen components that are made for reasons of simplification, convenience and safety profile in children who have sustained virologic suppression on their current regimen. When considering such a change, it is important to ensure that a child does not have virologic treatment failure. It is also critical to consider past episodes of ART, tolerability, and all prior drug resistance testing results in order to avoid choosing new ARV drugs for which archived drug resistance would **reemerge and** limit activity.²¹⁻²⁵ The evidence supporting many of these ARV changes is indirect, extrapolated from data about drug performance in initial therapy or follow-on therapy after treatment failure. When such changes are made, careful monitoring (e.g., viral load measurement 2–4 weeks after switch to new regimen) is important to ensure that virologic suppression is maintained.

Table 14: Examples of Changes in Antiretroviral Regimen Components that Are Made for Reasons of Simplification, Convenience, and Safety Profile in Children Who Have Sustained Virologic Suppression on Their Current Regimens^a (page 1 of 2)

ARV Drug(s)	Age	Body Size Attained	Potential ARV Regimen Change	Comment ^b
NRTIs				
ABC Twice Daily	≥1 year	Any	ABC once daily	See Abacavir in Appendix A: Pediatric Antiretroviral Drug Information for full discussion.
ZDV or ddl (or d4T^c)	≥1 year	N/A	ABC	Once-daily dosing (see Abacavir in Appendix A: Pediatric Antiretroviral Drug Information). Less long-term mitochondrial toxicity. TDF is a reasonable option for children unable to take ABC (HLA B5701 positive) who want to switch to a once-daily regimen.
	N/A	>35 kg	TAF or ABC	N/A
	Adolescence	Pubertal maturity (i.e., SMR IV or V)	TDF, TAF or ABC	Once-daily dosing. Less long-term mitochondrial toxicity. Coformulation with other ARV drugs can further reduce pill burden. TAF preferred over TDF for lower bone toxicity.
NNRTIs				
EFV	≥12 years	≥40 kg	ATV/r DRV/r DTG	Smaller pill (DTG), higher barrier to resistance given concern for adherence challenges developing in adolescents.
			RPV	DRV/r may be administered once daily in children aged ≥12 years without DRV resistance mutations.

Table 14: Examples of Changes in Antiretroviral Regimen Components that Are Made for Reasons of Simplification, Convenience, and Safety Profile in Children Who Have Sustained Virologic Suppression on Their Current Regimens^a (page 2 of 2)

ARV Drug(s)	Age	Body Size Attained	Potential ARV Regimen Change	Comment ^b
PIs				
LPV/r Twice Daily	≥1 year	≥3 kg	RAL	Better palatability. Less adverse lipid effect. Lower pill burden. Once-daily dosing (ATV/r).
	≥3 years	N/A	ATV/r	Once-daily dosing (EFV and ATV/r). Better palatability. Less adverse lipid effect. See Efavirenz in Appendix A: Pediatric Antiretroviral Drug Information regarding concerns about dosing for children aged <3 years.
			EFV	
			RAL	
			DTG (weighing ≥30 kg)	
			EVG (weighing ≥25 kg)	
	≥12 years	≥40 kg	DRV/r	Once-daily dosing possible. Lower pill burden.
			ATV/r	
			DTG	
			RPV	
Other				
Any Multi-Pill and/or Twice-Daily Regimen	Adolescence	For regimens with TDF: pubertal maturity (i.e., SMR IV or V)	Co-formulated: • TDF/FTC/EFV • TDF/FTC/EVG/COBI • TAF/FTC/EVG/COBI (weighing ≥35 kg) • TDF/FTC/RPV • TAF/FTC/RPV (weighing ≥35 kg) • ABC/3TC/DTG (weighing ≥40 kg) • TAF/FTC plus DTG	Once-daily dosing. Single pill. Alignment with adult regimens. TAF/FTC plus DTG may be more desirable because of small pill sizes even though it increases pill burden to 2 pills instead of 1. TAF-based regimens can be used with adolescents weighing ≥35 kg. Use ABC/3TC/DTG for adolescents weighing ≥40kg

^a This list is not exhaustive in that it does not necessarily list all potential options, but instead, shows examples of what kinds of changes can be made.

^b Comments relevant to the potential ARV change listed. Does not include all relevant information. Please refer to individual drug tables for full information.

^c Because of concerns about long-term adverse events, d4T should be replaced with a safer drug even before sustained virologic suppression is achieved (see [Stavudine](#) in [Appendix A: Pediatric Antiretroviral Drug Information](#)).

Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV/r = atazanavir/ritonavir; COBI = cobicistat; d4T = stavudine; ddI = didanosine; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FTC = emtricitabine; LPV/r = lopinavir/ritonavir; **NNRTI = non-nucleoside reverse transcriptase inhibitor**; NRTI = nucleoside reverse transcriptase inhibitor; **PI = protease inhibitor**; RAL = raltegravir; RPV=rilpivirine; SMR= sexual maturity rating (Tanner stage); TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

References

- Hsu AJ, Neptune A, Adams C, Hutton N, Agwu AL. Antiretroviral stewardship in a pediatric HIV clinic: development, implementation and improved clinical outcomes. *Pediatr Infect Dis J*. 2016;35(6):642-648. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26906161>.
- Maiese EM, Johnson PT, Bancroft T, Goolsby Hunter A, Wu AW. Quality of life of HIV-infected patients who switch antiretroviral medication due to side effects or other reasons. *Curr Med Res Opin*. 2016:1-8. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27552553>.
- Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. *JAMA*. 2010;304(10):1082-1090. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20511111>.

nlm.nih.gov/pubmed/20823434.

4. Kuhn L, Coovadia A, Strehlau R, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. *Lancet Infect Dis*. 2012;12(7):521-530. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22424722>.
5. Coovadia A, Abrams E, Strehlau R, et al., with the NEVEREST Study Team. Virologic efficacy of efavirenz maintenance therapy in nevirapine prophylaxis-exposed children. Abstract #73. Presented at: 21st Conference on Retroviruses and Opportunistic Infections. 2014. Boston, MA.
6. Coovadia A, Abrams EJ, Strehlau R, et al. Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in South Africa: a randomized clinical trial. *JAMA*. 2015;314(17):1808-1817. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26529159>.
7. Vigano A, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. *Antivir Ther*. 2005;10(8):917-924. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16430197>.
8. Fabiano V, Giacomet V, Vigano A, et al. Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz. *Eur J Pediatr*. 2013;172(8):1089-1096. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23636286>.
9. Rosso R, Nasi M, Di Biagio A, et al. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. *Pediatr Infect Dis J*. 2008;27(1):17-21. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18162932>.
10. Aupibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy. *HIV Med*. 2008;9(5):317-321. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18331562>.
11. Gonzalez-Tome MI, Amador JT, Pena MJ, Gomez ML, Conejo PR, Fontelos PM. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. *BMC Infect Dis*. 2008;8:144. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18945352>.
12. Foissac F, Blanche S, Dollfus C, et al. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents. *Br J Clin Pharmacol*. 2011;72(6):940-947. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21649692>.
13. Chokephaibulkit K, Prasitsuebsai W, Wittawatmongkol O, et al. Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥ 7 years. *Antivir Ther*. 2012;17(7):1263-1269. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22954687>.
14. Lyall H. Final results of Koncert: A randomized noninferiority trial of QD vs BD LPV/r dosing in children. Presented at: 21st Conference on Retroviruses and Opportunistic Infections. 2014. Boston, MA.
15. Paediatric European Network for Treatment of AIDS. Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children. *AIDS*. 2015;29(18):2447-2457. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26558544>.
16. Arribas JR, Girard PM, Paton N, et al. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. *HIV Med*. 2016;17(5):358-367. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26709605>.
17. Rokx C, Schurink CA, Boucher CA, Rijnders BJ. Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients. *J Antimicrob Chemother*. 2016;71(6):1632-1636. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26888910>.
18. Pinnetti C, Lorenzini P, Cozzi-Lepri A, et al. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication. *J Int AIDS Soc*. 2014;17(4 Suppl 3):19809. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25397553>.
19. Santos JR, Llibre JM, Bravo I, et al. Short communication: efficacy and safety of treatment simplification to lopinavir/ritonavir or darunavir/ritonavir monotherapy: a randomized clinical trial. *AIDS Res Hum Retroviruses*. 2016;32(5):452-455. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26781004>.

20. Kosalaraksa P, Ananworanich J, Puthanakit T, et al. Long-term lopinavir/ritonavir monotherapy in HIV-infected children. *Pediatr Infect Dis J*. 2013;32(4):350-353. Available at <https://www.ncbi.nlm.nih.gov/pubmed/23190774>.
21. Agwu AL, Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents. *J Int AIDS Soc*. 2013;16:18579. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23782477>.
22. Wensing AM, Calvez V, Gunthard HF, et al. 2015 Update of the drug resistance mutations in HIV-1. *Topics in Antiviral Medicine*. 2015;23(4):132-141. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26713503>.
23. Dehority W, Deville JG, Lujan-Zilbermann J, Spector SA, Viani RM. Effect of HIV genotypic drug resistance testing on the management and clinical course of HIV-infected children and adolescents. *Int J STD AIDS*. 2013;24(7):549-553. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23970770>.
24. Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. *J Virol*. 2005;79(15):9625-9634. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16014925>.
25. Kuritzkes DR. Preventing and managing antiretroviral drug resistance. *AIDS Patient Care STDS*. 2004;18(5):259-273. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15186710>.